Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer

BACKGROUND: Although co-inhibition of the angiogenesis and programmed death 1 (PD-1) pathways is proposed as an effective anticancer strategy, studies in Chinese patients with endometrial cancer are sufficient. Anlotinib is an oral multi-targeted tyrosine kinase inhibitor affecting tumor angiogenesi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wei, Ban, Xiaohua, Yang, Fan, Li, Jibin, Cheng, Xiaqin, Zhang, Rong, Huang, Xin, Huang, Yongwen, Li, Qiaqia, Qiu, Ya, Zheng, Min, Zhu, Xiaofeng, Li, Jundong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150151/
https://www.ncbi.nlm.nih.gov/pubmed/35623659
http://dx.doi.org/10.1136/jitc-2021-004338

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9150151/
https://www.ncbi.nlm.nih.gov/pubmed/35623659
http://dx.doi.org/10.1136/jitc-2021-004338

Ejemplares similares